Clinical trial
A Multicentre, Observational, Phase 4 Study to Evaluate the Safety and Tolerability of Lenvatinib in Patients With Advanced or Unresectable Hepatocellular Carcinoma (STELLAR)
NCT04763408 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Observational, Phase 4 Study to Evaluate the Safety and Tolerability of Lenvatinib in Patients With Advanced or Unresectable Hepatocellular Carcinoma (STELLAR)
- Lead sponsor
- Eisai Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 9, 2021
- Completion date
- December 13, 2023
- Enrollment
- 335 (actual)
- Sites
- 44
Conditions
As the registry lists them; a condition with its own page is linked.